BindingDB logo
myBDB logout

96 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27597413 58 Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.EBI Southern Medical University
27890378 20 Design and synthesis of 4,5,6,7-tetrahydro-1H-1,2-diazepin-7-one derivatives as a new series of Phosphodiesterase 4 (PDE4) inhibitors.EBI University of Genoa
27933955 123 Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.EBI Rhône-Poulenc Rorer
27299736 37 The"Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.EBI St. John's University
27289320 25 Synthesis and bioactivity of pyrazole and triazole derivatives as potential PDE4 inhibitors.EBI South China Agricultural University
26935942 41 Synthesis and evaluation of analogs of the phenylpyridazinone NPD-001 as potent trypanosomal TbrPDEB1 phosphodiesterase inhibitors and in vitro trypanocidals.EBI Mercachem
26681511 33 Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors.EBI Sanofi Research Center
26526739 35 Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.EBI Southern Medical University
26430878 102 Synthesis of Fluorine-Containing Phosphodiesterase 10A (PDE10A) Inhibitors and the In Vivo Evaluation of F-18 Labeled PDE10A PET Tracers in Rodent and Nonhuman Primate.EBI Washington University School of Medicine
26320621 13 Design, synthesis and biological evaluation of novel tetrahydroisoquinoline derivatives as potential PDE4 inhibitors.EBI South China Agricultural University
26288344 15 Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).EBI Novartis Institutes for Biomedical Research
25866242 55 2-(Isopropylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as selective phosphodiesterase 7 inhibitors with potent in vivo efficacy.EBI Kaken Pharmaceutical Co. Ltd
25127163 11 Repurposing human PDE4 inhibitors for neglected tropical diseases: design, synthesis and evaluation of cilomilast analogues as Trypanosoma brucei PDEB1 inhibitors.EBI Northeastern University
25126889 10 Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.EBI University of Genoa
24998378 62 Discovery of triazines as selective PDE4B versus PDE4D inhibitors.EBI Northern Illinois University
24881566 140 Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).EBI GlaxoSmithKline
25529739 43 Discovery and SAR study of 2-(4-pyridylamino)thieno[3,2-d]pyrimidin-4(3H)-ones as soluble and highly potent PDE7 inhibitors.EBI Kyoto 607-8042
25383422 48 Discovery of 2-(cyclopentylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as a new series of potent phosphodiesterase 7 inhibitors.EBI Kyoto 607-8042
25264825 54 Modulation of cAMP-specific PDE without emetogenic activity: new sulfide-like PDE7 inhibitors.EBI Centro de Investigaciones Biol�gicas (CSIC)
25149511 34 Novel Roflumilast analogs as soft PDE4 inhibitors.EBI Amakem N.V.
24785301 83 Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD.EBI AstraZeneca
23415088 4 Novel imidazophenoxazine-4-sulfonamides: their synthesis and evaluation as potential inhibitors of PDE4.EBI Medicinal Chemistry Laboratory, Research Centre, CKM Arts and Science College, Warangal 506 006, Andhra Pradesh, India.
23380174 2 Montmorillonite K-10 catalyzed green synthesis of 2,6-unsubstituted dihydropyridines as potential inhibitors of PDE4.EBI Dr. Reddy's Laboratories Limited
23375225 11 Hybrids consisting of the pharmacophores of salmeterol and roflumilast or phthalazinone: dualß2-adrenoceptor agonists-PDE4 inhibitors for the treatment of COPD.EBI Sun Yat-sen University
23301853 4 Benzoquinones and terphenyl compounds as phosphodiesterase-4B inhibitors from a fungus of the order Chaetothyriales (MSX 47445).EBI University of North Carolina at Greensboro
23200255 50 Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration.EBI Kyorin Pharmaceutical Co., Ltd
23409953 13 Discovery of novel Trypanosoma brucei phosphodiesterase B1 inhibitors by virtual screening against the unliganded TbrPDEB1 crystal structure.EBI VU University Amsterdam
23294698 8 Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors.EBI University of Hyderabad Campus
20202837 51 The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist.EBI Medicines Research Centre
19932963 6 Addressing species specific metabolism and solubility issues in a quinoline series of oral PDE4 inhibitors.EBI GlaxoSmithKline
19656678 25 Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.EBI GlaxoSmithKline Medicines Research Centre
19195882 27 Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.EBI GlaxoSmithKline Medicines Research Centre
18539455 31 Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.EBI GlaxoSmithKline Medicines Research Centre
22437115 66 Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A).EBI GlaxoSmithKline R&D
22963052 38 Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.EBI VU University Amsterdam
22891752 18 Design, synthesis, and pharmacological evaluation of N-acylhydrazones and novel conformationally constrained compounds as selective and potent orally active phosphodiesterase-4 inhibitors.EBI Universidade Federal do Rio de Janeiro
22889281 36 Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.EBI Novartis Institutes for Biomedical Research
22884989 42 Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones.EBI Kyorin Pharmaceutical Co., Ltd.
22642587 2 Langkolide, a 32-membered macrolactone antibiotic produced by Streptomyces sp. Acta 3062.EBI Technische Universit£t Berlin
22385507 20 Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.EBI Instituto de Qu£mica M£dica (CSIC)
22483586 10 Moracin M from Morus alba L. is a natural phosphodiesterase-4 inhibitor.EBI Sun Yat-Sen University
22464134 1 Conformationally restricted novel pyrazole derivatives: synthesis of 1,8-disubstituted 5,5-dimethyl-4,5-dihydro-1H-benzo[g]indazoles as a new class of PDE4 inhibitors.EBI CiVentiChem (India) Private Limited
22401864 61 Discovery of oxazole-based PDE4 inhibitors with picomolar potency.EBI Merck Research Laboratories
20188577 23 In silico search for multi-target anti-inflammatories in Chinese herbs and formulas.EBI King's College London
18686943 28 Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.EBI Matrix Laboratories Limited
18222088 1 Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.EBI Purdue University
18304812 29 Rhodanine derivatives as novel inhibitors of PDE4.EBI University of Paisley
17337182 23 Potent and selective xanthine-based inhibitors of phosphodiesterase 5.EBI Novartis Institutes of Biomedical Research
17228876 36 SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.EBI Pfizer Global Research and Development
16168647 80 Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.EBI Merck Frosst Centre for Therapeutic Research
11844693 28 Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.EBI Janssen-Cilag
11755362 16 Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.EBI Novartis Pharma AG
22386978 2 C-C bond formation at C-2 of a quinoline ring: synthesis of 2-(1H-indol-3-yl)quinoline-3-carbonitrile derivatives as a new class of PDE4 inhibitors.EBI University of Hyderabad Campus
22321214 42 Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.EBI AstraZeneca
22297114 20 Dualß2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.EBI Sun Yat-sen University
22336247 20 Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity.EBI Kyorin Pharmaceutical Co. Ltd.
22142545 96 Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.EBI Merck Research Laboratories
21955943 47 Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region.EBI Pfizer Inc.
21871695 46 Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.EBI Rhône-Poulenc Rorer
20933411 69 Discovery of MK-0952, a selective PDE4 inhibitor for the treatment of long-term memory loss and mild cognitive impairment.EBI Merck Frosst Centre for Therapeutic Research
19447034 76 Discovery of selective PDE4B inhibitors.EBI Asahi Kasei Pharma Corporation
21530250 73 Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.EBI Heriot-Watt University
21189023 66 Synthesis and molecular modeling of novel tetrahydro-ß-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties.EBI German University in Cairo
20825218 69 Synthesis and biological activity of pyrido[3',2':4,5]thieno[3,2-d]pyrimidines as phosphodiesterase type 4 inhibitors.EBI Rhône-Poulenc Rorer
20709547 69 The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors.EBI Merck Frosst Centre for Therapeutic Research
20378348 21 Water-soluble PDE4 inhibitors for the treatment of dry eye.EBI Kalypsys, Inc.
20202838 62 Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors.EBI Pfizer Global Research and Development
20196613 32 Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).EBI Pfizer Global Research and Development
19631533 126 Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.EBI Pfizer Global Research and Development
19500884 1 Studies towards the identification of putative bioactive conformation of potent vasodilator arylidene N-acylhydrazone derivatives.EBI Universidade Federal do Rio de Janeiro
 31 Phosphodiesterase type IV (PDE IV) inhibition. Synthesis and evaluation of a series of 1,3,4-trisubstituted pyrrolidinesEBI TBA
19339180 69 The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.EBI Pfizer Global Research and Development
18945617 50 Succinyl hydroxamates as potent and selective non-peptidic inhibitors of procollagen C-proteinase: design, synthesis, and evaluation as topically applied, dermal anti-scarring agents.EBI Pfizer Global Research and Development
17683932 55 Discovery of a highly potent series of oxazole-based phosphodiesterase 4 inhibitors.EBI Schering-Plough Research Institute
16516471 114 Nitrogen-bridged substituted 8-arylquinolines as potent PDE IV inhibitors.EBI Merck Frosst Center for Therapeutic Research
16275071 26 A new chemical tool for exploring the physiological function of the PDE2 isozyme.EBI Pfizer, Inc.
16263279 37 A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.EBI Pfizer, Inc.
9464356 24 Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.EBI Pfizer Inc.
7490734 9 Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase.EBI Glaxo Wellcome Research
19525117 30 Identification of PDE4B Over 4D subtype-selective inhibitors revealing an unprecedented binding mode.BDB GSK
19256502 38 Dual inhibitors of phosphodiesterase-4 and serotonin reuptake.BDB Human BioMolecular Research Institute
15685167 42 A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.BDB Plexxikon
15576036 110 Structural basis for the activity of drugs that inhibit phosphodiesterases.BDB Plexxikon
15715490 145 8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyladenine: highly potent and selective PDE4 inhibitors.BDB Purdue Pharma LP
16539372 8 Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.BDB University of North Carolina at Chapel Hill